JEPQ ETF: Volmageddon 2.0 Fears Overblown

sefa ozel Recently, I have seen many investment analysts and news outlets discuss the possibility of ‘Volmageddon 2.0’ (Figure 1). Figure 1 – Option income assets have grown rapidly in recent years (Elliot wave International via X) According to these analysts and reporters, investors pouring billions into ETFs selling options is betting on calm markets…

Read More

Petrobras: We Shouldn’t Be Unnerved By The Overblown Dividend Crisis (NYSE:PBR)

FabioIm Petróleo Brasileiro S.A. (NYSE:PBR) investors endured a torrid two months as they dealt with the uncertainties emanating from Petrobras’s extraordinary dividend payout. As a reminder, the government seems displeased with paying these dividends to shareholders. Still, the irony is that the Brazilian government also needs the payout to support its fiscal budget. Moreover, the…

Read More

Petrobras’ Dividend Crisis Is Overblown (NYSE:PBR)

herraez Petrobras (NYSE:PBR) has declined almost 20% over the past month as investors remain concerned about what were once record breaking dividends for the company. Brazil’s president has summoned the company’s CEO over concerns about this crisis. That’s despite the crisis being triggered by a government that wanted the company to instead invest dividends. Petrobras…

Read More

Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown (NASDAQ:MDGL)

Gilnature On Tuesday Feb 6, when Eli Lilly (LLY) announced their Q4 2023 report, the stocks of NASH (nonalcoholic steatohepatitis) drug developers, e.g. Madrigal Pharmaceuticals (NASDAQ:MDGL), Viking Therapeutics (VKTX), Akero Therapeutics (AKRO), Sagimet Biosciences (SGMT) etc., all come under selling pressure. The reason for the stock market sell-off appears to be the perception that LLY’s…

Read More